Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2007

01.12.2007 | Gastrointestinal Oncology

Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma

verfasst von: Ahmad Faried, MD, PhD, Leri S. Faried, MD, Nurhayat Usman, MD, Hiroyuki Kato, MD, PhD, Hiroyuki Kuwano, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Rho GTPases are involved in the organization of a microfilament network, cell-to-cell interaction, and malignant transformation. To elucidate the role of Rho GTPases in esophageal squamous cell carcinoma (ESCC), we compared the levels of RhoA and RhoC mRNA from ESCC with the corresponding normal tissue originating from the same patients.

Methods

Real-time reverse transcriptase–polymerase chain reaction was performed to observe rhoA and rhoC in esophageal cell lines. Next, the mRNA levels of rhoA and rhoC were evaluated from 50 patients.

Results

The rhoA and rhoC were higher in ESCC cell lines than in noncancerous esophageal cell. rhoC was overexpressed in TTn, which was obtained directly from a surgical specimen of a metastatic lesion of ESCC in the mandible. rhoA and rhoC were significantly higher in ESCC patient than in the normal counterparts (P = .0022 and P < .0001, respectively). rhoA correlated with tumor differentiation and rhoC correlated with an advanced tumor, node, metastasis system classifications. rhoA and rhoC in ESCC showed a positive correlation (P = .008). Patients with rhoA overexpression showed a significantly poorer prognosis than those with rhoA underexpression (P = .044).

Conclusions

To our knowledge, this study is the first in which the expression of RhoA and RhoC at the mRNA level in ESCC was examined and compared with its normal counterpart. Our results suggest that rhoA and rhoC are involved in ESCC progression and useful as prognostic markers. Further study will be needed to examine the therapeutic potential of the Rho GTPase inhibitor as a promising anticancer therapy, especially in ESCC.
Literatur
1.
Zurück zum Zitat Berrino F, Sant M, Verdecchia A, et al., eds. Survival of Cancer Patients in Europe: The EUROCARE Study. IARC Scientific Publication No. 132. Lyon, France: IARC 1995 Berrino F, Sant M, Verdecchia A, et al., eds. Survival of Cancer Patients in Europe: The EUROCARE Study. IARC Scientific Publication No. 132. Lyon, France: IARC 1995
2.
Zurück zum Zitat Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462–7PubMedCrossRef Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462–7PubMedCrossRef
3.
Zurück zum Zitat Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305–13PubMed Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305–13PubMed
5.
Zurück zum Zitat del Peso L, Hernandez-Alcoceba R, Embade N, et al. Rho proteins induce metastatic property in vivo. Oncogene 1997;15:3047–57PubMedCrossRef del Peso L, Hernandez-Alcoceba R, Embade N, et al. Rho proteins induce metastatic property in vivo. Oncogene 1997;15:3047–57PubMedCrossRef
6.
Zurück zum Zitat Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682–7PubMedCrossRef Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682–7PubMedCrossRef
7.
Zurück zum Zitat Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83:861–70PubMed Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83:861–70PubMed
8.
Zurück zum Zitat Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632–41PubMed Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632–41PubMed
9.
Zurück zum Zitat Faried A, Nakajima M, Sohda M, Miyazaki T, Kato H, Kuwano H. Correlation between RhoA overexpression and tumor progression in esophageal squamous cell carcinoma. Eur J Surg Oncol 2005;31:410–4PubMedCrossRef Faried A, Nakajima M, Sohda M, Miyazaki T, Kato H, Kuwano H. Correlation between RhoA overexpression and tumor progression in esophageal squamous cell carcinoma. Eur J Surg Oncol 2005;31:410–4PubMedCrossRef
10.
Zurück zum Zitat Li XR, Ji F, Ouyang J, Wu W, Qian LY, Yang KY. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol 2006;32:1130–4PubMedCrossRef Li XR, Ji F, Ouyang J, Wu W, Qian LY, Yang KY. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol 2006;32:1130–4PubMedCrossRef
11.
Zurück zum Zitat Kamai T, Arai K, Tsujii M, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 2001;87:227–31PubMedCrossRef Kamai T, Arai K, Tsujii M, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 2001;87:227–31PubMedCrossRef
12.
Zurück zum Zitat Kleer CG, van Golen KL, Zhang Y, et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002;160:579–84PubMed Kleer CG, van Golen KL, Zhang Y, et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002;160:579–84PubMed
13.
Zurück zum Zitat Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinoma of the breast. Breast Cancer Res Treat 2005;93:101–10PubMedCrossRef Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinoma of the breast. Breast Cancer Res Treat 2005;93:101–10PubMedCrossRef
14.
Zurück zum Zitat Kleer CG, Teknos TN, Islam M, et al. RhoC GTPase as a potential marker of lymph node metastasis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:4485–90PubMedCrossRef Kleer CG, Teknos TN, Islam M, et al. RhoC GTPase as a potential marker of lymph node metastasis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:4485–90PubMedCrossRef
15.
Zurück zum Zitat Suwa H, Ohshio G, Imamura T, et al. Overexpression of the rhoC gene correlates with the progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147–52PubMed Suwa H, Ohshio G, Imamura T, et al. Overexpression of the rhoC gene correlates with the progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147–52PubMed
16.
Zurück zum Zitat Wang W, Yang LY, Huang, et al. Genomic analysis revels RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 2004;90:2349–55PubMed Wang W, Yang LY, Huang, et al. Genomic analysis revels RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 2004;90:2349–55PubMed
17.
Zurück zum Zitat Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532–5PubMedCrossRef Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532–5PubMedCrossRef
18.
Zurück zum Zitat van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60:5832–8PubMed van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60:5832–8PubMed
19.
Zurück zum Zitat Faried A, Faried LS, Kimura H, et al. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 2006;42:1455–65PubMedCrossRef Faried A, Faried LS, Kimura H, et al. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 2006;42:1455–65PubMedCrossRef
20.
Zurück zum Zitat Sobin LH, Wittekind C, eds. TNM: Classification of Malignant Tumours. 6th ed. New York: Wiley, 2002 Sobin LH, Wittekind C, eds. TNM: Classification of Malignant Tumours. 6th ed. New York: Wiley, 2002
21.
Zurück zum Zitat Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993;119:441–9PubMedCrossRef Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993;119:441–9PubMedCrossRef
22.
Zurück zum Zitat Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Saito K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (TT and TTn) established from the oral tumor. Jpn J Oral Maxillofac Surg 1990;36:307–16 Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Saito K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (TT and TTn) established from the oral tumor. Jpn J Oral Maxillofac Surg 1990;36:307–16
23.
Zurück zum Zitat Sashiyama H, Shino Y, Sakao S, et al. Alteration of integrin expression rates to malignant progression of human papillomavirus-immortalized esophageal keratinocytes. Cancer Lett 2002;177:21–8PubMedCrossRef Sashiyama H, Shino Y, Sakao S, et al. Alteration of integrin expression rates to malignant progression of human papillomavirus-immortalized esophageal keratinocytes. Cancer Lett 2002;177:21–8PubMedCrossRef
24.
Zurück zum Zitat Xu M, Miller MS. Determination of murine fetal reverse transcriptase–polymerase chain reaction. Toxicol Appl Pharmacol 2004;201:295–302PubMedCrossRef Xu M, Miller MS. Determination of murine fetal reverse transcriptase–polymerase chain reaction. Toxicol Appl Pharmacol 2004;201:295–302PubMedCrossRef
25.
Zurück zum Zitat R statistical software. Available at: ftp://ftp.u-aizu.ac.jp/pub/lang/R/CRAN/ R statistical software. Available at: ftp://ftp.u-aizu.ac.jp/pub/lang/R/CRAN/
26.
Zurück zum Zitat Zhou J, Zhao LQ, Xiong MM, et al. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. World J Gastroenterol 2003;9:9–15PubMed Zhou J, Zhao LQ, Xiong MM, et al. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. World J Gastroenterol 2003;9:9–15PubMed
27.
Zurück zum Zitat Lawler K, Foran E, O’Sullivan G, Long A, Kenny D. Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. Am J Physiol Cell Physiol 2006;291:C668–77PubMedCrossRef Lawler K, Foran E, O’Sullivan G, Long A, Kenny D. Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. Am J Physiol Cell Physiol 2006;291:C668–77PubMedCrossRef
28.
Zurück zum Zitat Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241–69PubMedCrossRef Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241–69PubMedCrossRef
29.
Zurück zum Zitat Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem 1992;267:20033–8PubMed Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem 1992;267:20033–8PubMed
30.
Zurück zum Zitat van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyltransferase inhibitor. Mol Cancer Ther 2002;1:575–83PubMed van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyltransferase inhibitor. Mol Cancer Ther 2002;1:575–83PubMed
31.
Zurück zum Zitat Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2:941–8PubMed Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2:941–8PubMed
32.
Zurück zum Zitat Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor alpha–mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sci 2006;79:1484–92PubMedCrossRef Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor alpha–mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sci 2006;79:1484–92PubMedCrossRef
33.
Zurück zum Zitat Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer 2001;84:886–91PubMedCrossRef Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer 2001;84:886–91PubMedCrossRef
34.
Zurück zum Zitat Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221–5PubMedCrossRef Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221–5PubMedCrossRef
35.
Zurück zum Zitat Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000;91:811–6PubMed Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000;91:811–6PubMed
36.
Zurück zum Zitat Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652–9PubMedCrossRef Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652–9PubMedCrossRef
Metadaten
Titel
Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma
verfasst von
Ahmad Faried, MD, PhD
Leri S. Faried, MD
Nurhayat Usman, MD
Hiroyuki Kato, MD, PhD
Hiroyuki Kuwano, MD, PhD
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9562-x

Weitere Artikel der Ausgabe 12/2007

Annals of Surgical Oncology 12/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.